

1 **Impact of pretreatment asymptomatic renal dysfunction on the**
2 **clinical course after esophagectomy**

3 Yuki Kirihataya¹ · Kohei Wakatsuki¹ · Sohei Matsumoto¹ · Hiroshi Nakade¹ · Tomohiro
4 Kunishige¹ · Shintaro Miyao¹ · Masayuki Sho¹

5

6 **A brief title:** Asymptomatic renal dysfunction as risk of complications after esophagectomy

7

8 ¹Department of Surgery, Nara Medical University School of Medicine, Nara, Japan

9

10 **Correspondence to:** Masayuki Sho

11 Department of Surgery, Nara Medical University

12 840 Shijo-cho, Kashihara, Nara 634-8522, Japan

13 E-mail: m-sho@naramed-u.ac.jp

14 Tel.: +81-744-29-8863, Fax: +81-744-24-6866

15

16 **The article type: Original Article (Clinical Original)**

17

18 **Keywords:** Esophagectomy · Renal dysfunction · Postoperative complication · Surgery

19

1 **Abstract**

2 **Purpose** Although recent large-scale clinical studies have shown that preoperative renal
3 insufficiency is associated with an increased risk of postoperative complications after
4 esophagectomy, whether or not asymptomatic renal dysfunction has an impact on the
5 postoperative course after esophagectomy is unclear.

6 **Methods** A total of 177 patients who underwent esophagectomy between May 2009 and
7 December 2018 were enrolled. The renal function was evaluated based on the pretreatment
8 estimated glomerular filtration rate (eGFR). Patients were divided into two groups according
9 to the eGFR cut-off value of 55 ml/min per 1.73 m².

10 **Results** Seventeen patients were classified as the low eGFR group, while 160 were
11 classified as the normal eGFR group. The rate of severe complications in the low eGFR group
12 was significantly higher than that in the normal eGFR group. Only a low eGFR was a
13 significant complication risk factor. However, there were no marked differences in the
14 mortality or survival between the low and normal eGFR groups.

15 **Conclusion** We demonstrated for the first time that pretreatment asymptomatic renal
16 dysfunction may be a significant risk factor for severe morbidity after esophagectomy.

1 **Introduction**

2 Esophagectomy for esophageal cancer is associated with higher morbidity and mortality rates
3 (2.7%–11.4%) than other gastrointestinal surgeries, although advances in surgical techniques
4 and perioperative management have made it possible to perform esophagectomy relatively
5 safely [1,2]. Preoperative complications are reportedly associated with postoperative
6 complications in cases of esophageal cancer [3,4]. An older age, poor performance status,
7 corticosteroid use, squamous cell cancer, chronic lung disease, and malnutrition are known
8 predictors of complications after standard esophagectomy [5–7]. Postoperative sepsis reflects
9 a deep impairment of the immune response, which is potentially associated with cancer
10 recurrence and mortality [8]. Information on the risks of postoperative complications is
11 important for performing proper perioperative management and obtaining informed consent
12 from patients.

13 Renal dysfunction remains a major risk factor because it is related to not only the
14 metabolic and coagulopathic disorders secondary to uremia and anuria but also other co-
15 morbidities [9,10]. Preoperative renal insufficiency is a well-known risk factor for
16 postoperative complications after cardiac and vascular surgery [11,12]. There is a
17 subpopulation of patients with asymptomatic renal dysfunction with no need for hemodialysis.
18 Preoperative renal failure and postoperative complications have also been reported for cancer.
19 In pancreatic cancer, Nagai et al. [13] reported that mild asymptomatic renal dysfunction was

1 an independent risk factor for severe postoperative complications and grade B/C pancreatic
2 fistula after pancreatoduodenectomy when patients were divided into two groups according to
3 an estimated glomerular filtration rate (eGFR) cut-off value of 55 ml/min per 1.73 m². In gastric
4 cancer, Matsumoto et al. [14] reported that the incidences of anastomotic leakage and
5 intraabdominal abscess in the mild CKD group was higher than that in the control group when
6 patients with gastric cancer were divided according to their eGFR. Such asymptomatic renal
7 dysfunction has thus been reported to be a risk for surgery for gastric and pancreatic cancer.
8 However, to our knowledge, no studies have addressed the impact of such asymptomatic renal
9 dysfunction on the postoperative outcome after esophagectomy.

10 Given the above, the present study tried to clarify the short- and long-term outcomes
11 after esophagectomy in patients with such asymptomatic renal dysfunction.

12

13

14 **Patients and methods**

15 **Patients**

16 A total of 192 patients underwent esophagectomy between May 2009 and December 2018 in
17 Nara Medical University Hospital. Twelve patients with R2 resection and three treatment-
18 related deaths were excluded from this study. The remaining 177 patients were retrospectively
19 analyzed.

1 Patients provided their written informed consent before treatment according to the rules
2 and regulations of our institution. This study was approved by the ethics committees of Nara
3 Medical University Hospital (approval no. 2540).

4

5 **Data and definition**

6 A comprehensive review of the medical records was performed to evaluate various
7 clinicopathological factors including patient demographics, medical comorbidities,
8 preoperative laboratory values, tumor pathological characteristics, and perioperative data. The
9 pathological diagnosis was classified as benign disease, malignant disease other than squamous
10 cell carcinoma (SCC), and SCC. As a result, 1 benign primary disease, 32 malignant tumors
11 other than SCC, and 144 SCCs were included. According to medical comorbidities,
12 cardiovascular disease included coronary artery disease, atrial fibrillation, and cerebral
13 infarction. Renal disease included diabetic nephropathy, and chronic kidney disease.
14 Respiratory disorder included chronic obstructive pulmonary disease, bronchial asthma,
15 interstitial pneumonia, and bronchial ectasia. A total of 108 patients received neoadjuvant
16 chemotherapy. The renal function was evaluated by calculating the eGFR based on the results
17 of laboratory examination at the first visit to our hospital. The eGFR was calculated using the
18 following formula: $eGFR (\text{ml/min per } 1.73 \text{ m}^2) = 194 \times sCr^{-1.094} \times \text{Age}^{-0.287} (\times 0.739 \text{ if}$
19 the patient is female) [15].

1

2 **Outcome assessments**

3 The incidence of postoperative complications was evaluated, and the severity of complications
4 was defined according to the Clavien-Dindo classification [16]. If more than one complication
5 occurred in a single patient, the most severe grade was considered for the present analysis.
6 Severe complications were defined as those of grade IIIb and higher. We further evaluated
7 various outcome parameters, including the length of the postoperative hospital stay and the
8 prognosis. The date of the last follow-up was November 2019.

9

10 **Statistical analyses**

11 The parameters were compared using Mann-Whitney U Test, the χ^2 test, or Fisher's exact test
12 as appropriate. Continuous variables were expressed as the mean and standard deviation. The
13 odds ratios (OR) for severe postoperative complications were calculated using logistic
14 regression model. The overall survival (OS) was calculated from the date of initial treatment
15 with surgery until death or the last follow-up. The survival curve was estimated according to
16 the Kaplan–Meier method, and differences were analyzed using the log-rank test. All reported
17 P-values were two-sided. P-value of <0.05 was considered statistically significant, and
18 confidence intervals (CIs) were calculated at the 95% level. The statistical analyses were
19 performed using the SPSS software program, version 19.0 (SPSS, Chicago, IL, USA).

1

2

3 **Results**

4 **Cut-off value of the eGFR**

5 To determine the optimal cut-off value of the eGFR to predict postoperative complications, we
6 set and evaluated various eGFR values in relation to complications of grade IIIb and higher. As
7 a result, we defined 55 ml/min per 1.73 m² as the cut-off value and classified all patients into
8 either low or normal eGFR groups based on this value. A total of 160 patients (90.4%) with an
9 eGFR of ≥ 55 ml/min per 1.73 m² were classified as the normal eGFR group, while the 17
10 patients (9.6%) with an eGFR of < 55 ml/min per 1.73 m² were classified as the low eGFR
11 group (Fig. 1).

12

13 **Patient clinicopathological characteristics according to the eGFR status**

14 The patient characteristics of each group are summarized in Table 1. The patients in the low
15 eGFR group were significantly older than those in the normal eGFR group ($p < 0.01$). There
16 were more men in the low eGFR group than in the normal eGFR group ($p = 0.04$). While the
17 serum creatinine level in the low eGFR group was significantly higher than that in the normal
18 eGFR group ($p < 0.01$), there were no marked differences in the hemoglobin or albumin values
19 between the two groups. There were also no marked differences in preoperative comorbidities,

1 tumor location, tumor size, clinical and pathological T-factor, clinical or pathological N-factor,
2 stage, reconstructed substitute, extent of lymphadenectomy, number of dissected nodes, or rate
3 of residual tumor between the two groups. Preoperative therapy was performed more frequently
4 in the normal eGFR group than in the low group, although the difference did not reach
5 statistical significance ($p = 0.07$).

6

7 **Perioperative data**

8 We then compared the perioperative data between the two groups (Table 2). There were no
9 significant differences between the two groups in the operating time or intraoperative blood
10 loss. In total, 108 patients (61%) developed postoperative complications. While there were no
11 marked differences between the two groups in total postoperative complications, the rate of
12 respiratory events was significantly higher in the low eGFR group than in the normal eGFR
13 group ($p = 0.02$). Respiratory events were aspiration pneumonia in five of six cases in the low
14 eGFR group, and two of those five cases required intensive-care unit (ICU) management.
15 Furthermore, the low eGFR group had a higher rate of severe complications (IIIb and higher
16 in Clavien-Dindo classification) than the normal eGFR group (24% vs. 7%, $p = 0.04$).

17

18 **Risk factors for severe complications**

1 Next, we analyzed the risk factors for severe postoperative complications after esophagectomy.

2 The statistical analysis indicated that only a low eGFR was a significant risk factor for the

3 incidence of severe complications (Table 3).

4

5 **The postoperative survival and recurrence**

6 Finally, we examined the impact of the eGFR on the patient prognosis. As shown in Figure 2,

7 there was a tendency toward differences in the OS rate between the groups ($p = 0.08$). There

8 were no significant differences in the rate of death from other diseases between the normal

9 eGFR group (17 of 160; 11%) and the low eGFR group (2 of 17; 12%) ($p = 0.58$). In the normal

10 eGFR group, 44 out of 160 cases relapsed, and in the low eGFR group, 6 out of 17 cases

11 relapsed, but there was no significant difference between the groups ($p = 0.49$). There were

12 also no significant differences between the groups in any of the recurrence patterns, including

13 lymphogenous, hematogenous, disseminated, and local (normal eGFR group vs. low eGFR

14 group; lymphogenous: 44 [28%] vs. 6 [35%], $p = 0.28$; hematogenous: 22 [14%] vs. 4 [24%],

15 $p = 0.17$; disseminated: 4 [3%] vs. 1 [6%], $p = 0.42$; local: 10 [6%] vs. 2 [12%], $p = 0.39$).

16 Regarding the cause of death, there were no significant differences between the normal and

17 low eGFR groups (death from cancer: 39 [23%] vs. 6 [35%], $p = 0.33$; death from other

18 diseases: 17 [11%] vs. 2 [2%], $p = 1.00$). Within 1 year, 3 out of 160 (2%) in the normal eGFR

19 group and 2 out of 17 (12%) in the low group died from other diseases.

1

2

3 **Discussion**

4 Some studies have reported that preoperative renal insufficiency was associated with increased
5 postoperative complications after various types of surgery, including cardiac and general
6 surgery [11,12,17]. The present findings suggest that patients with pretreatment asymptomatic
7 renal dysfunction might be at an increased risk for morbidity and mortality after esophageal
8 resection. Accordingly, we obtained a number of important findings, as described below.

9 First, there were significant correlations between a low eGFR and advanced age, while
10 there were no significant correlations between a low eGFR and perioperative variables. Data
11 suggest that asymptomatic renal dysfunction may represent patient frailty. Second, there were
12 significant correlations between the eGFR status and grade IIIb/IV complications ($p = 0.04$).
13 In particular, there was a correlation between a low eGFR and the incidence of respiratory
14 complications ($p = 0.02$). The statistical analysis indicated that only a low eGFR was an
15 independent risk factor for grade IIIb/IV complications. Therefore, our data suggest that
16 asymptomatic renal dysfunction had a significant negative impact on clinically relevant
17 postoperative complications after esophagectomy.

18 There are several mechanisms potentially underlying the association of asymptomatic
19 renal dysfunction with increased morbidity after esophagectomy. First, the tissue vulnerability

1 in patients with renal dysfunction may be related to increased complications [18]. Second,
2 perioperative fluid management may be involved. To prevent renal insufficiency, excessive
3 fluids may have been administered to patients with mildly elevated serum creatinine levels.
4 Third, a number of studies have shown that renal insufficiency is associated with an impaired
5 immune system in humans [19,20]. For instance, uremia causes inflammation and reduces the
6 immune response, thereby resulting in increased susceptibility to infection. Although relatively
7 few studies have addressed the impact of mild renal dysfunction on immunity, a potentially
8 inadequate immune response may have exacerbated the severity of complications after
9 esophagectomy [21]. An important question how long does it take for asymptomatic renal
10 dysfunction to induce various adverse influences on tissue vulnerability and immune system
11 may be raised. Although it is likely to take considerably long time, there is no study to address
12 this critical issue.

13 Next, considering renal insufficiency and increased respiratory complications, previous
14 reports have reported that the age, Brookman index, chronic obstructive pulmonary disease,
15 delirium, and clinical stage are risk factors for postoperative pulmonary complications [22,23].
16 The incidence of pulmonary morbidities after esophagectomy is high, reportedly occurring in
17 13.4%–38.2% of cases, and can be a major cause of surgery-related mortality [24,25]. In the
18 present study, we showed that postoperative pulmonary complications were more frequent in
19 the low eGFR group than in the normal eGFR group. Although the precise mechanisms of

1 increased risk of respiratory complications in patients with mild renal dysfunction remain
2 unclear, there are potential reasons. First, as mentioned above, perioperative fluid infusion may
3 be involved. However, we found that there was no significant difference in daily fluid balance
4 during surgery and the intensive care unit stay between the normal and low eGFR groups (data
5 not shown). Although it is still controversial about optimal fluid management, it is unlikely that
6 perioperative water balance simply cause pulmonary complications after esophagectomy [18].
7 Second, the impaired swallowing function in older patients might be related to the increased
8 risk of aspiration pneumonia, since the patients in the low eGFR group were significantly older
9 compared to the normal eGFR group. However, there was no significant direct relationship
10 between patients' age and respiratory complications ($p = 0.25$). Third, the renal dysfunction
11 may cause chronic inflammation and endothelial dysfunction, thereby resulting in pulmonary
12 edema and worsen respiratory status after highly invasive surgery. Furthermore, renal
13 dysfunction may also cause the impaired immune function leading to susceptibility to infection.
14 Taken together, the respiratory complications may be based on multiple reasons and
15 mechanisms in patients with mild renal dysfunction. Further studies are required to clarify the
16 underlying mechanisms and establish the optimal perioperative management approach after
17 esophagectomy.

18 Finally, we evaluated the impact of asymptomatic renal dysfunction on the patient
19 survival. Our data also indicated that asymptomatic renal dysfunction had no significant impact

1 on mortality after esophagectomy. Furthermore, the results also demonstrated that
2 asymptomatic renal dysfunction had no impact on the patient prognosis, although severe
3 complications increased, regardless of the original disease pathology. However, the survival
4 rate tended to be lower in the low eGFR group than in the normal eGFR group, while there
5 were no marked differences in the type or rate of recurrence between the two groups. Although
6 the true impact of pretreatment asymptomatic renal dysfunction on the patient prognosis
7 remains unclear, the relatively low rate of preoperative therapies might have been associated
8 with the poor prognosis in the patients in the low eGFR group. Taken together, these findings
9 suggest that esophagectomy may be justified for patients with renal dysfunction, even if there
10 are increased risks of postoperative complications—specifically respiratory events—after
11 esophagectomy.

12 Several limitations should be considered before drawing a definitive conclusion. First,
13 this was retrospective study performed at a single center with a relatively small sample size.
14 Furthermore, whether or not the eGFR cut-off value of 55 ml/min per 1.73 m² used in this study
15 is indeed optimum remains unclear. These findings should be prospectively validated in larger
16 cohort in the future.

17 In conclusion, to our knowledge, this is the first report to address the clinical impact of
18 pretreatment asymptomatic renal dysfunction on the postoperative clinical course after
19 esophagectomy. We should be aware that asymptomatic renal dysfunction may be a significant

1 risk factor for severe morbidity after esophagectomy. Although it had no impact on the
2 mortality or long-term survival, performing careful postoperative management and obtaining
3 proper informed consent from patients with renal dysfunction are needed.
4

1 **References**

- 2 1 Yoshida N, Watanabe M, Baba Y, Iwagami S, Ishimoto T, Iwatsuki M, et al. Risk factors
3 for pulmonary complications after esophagectomy for esophageal cancer. *Surg Today*.
4 2014;44(3):526–32.
- 5 2 Fuchs HF, Harnsberger CR, Broderick RC, Chang DC, Sandler BJ, Jacobsen GR, et al.
6 Mortality after esophagectomy is heavily impacted by center volume : retrospective
7 analysis of the Nationwide Inpatient Sample. *Surg Endosc*. 2017;31(6):2491–7.
- 8 3 Kataoka K, Takeuchi H, Igaki H, Ozawa S, Kato K, Ando N, et al. Prognostic impact of
9 postoperative morbidity after esophagectomy for esophageal cancer: exploratory
10 analysis of JCOG9907. *Ann Surg*. 2017;265(6):1152–7.
- 11 4 Linden PA, Towe CW, Watson TJ, Low DE, Cassivi SD, Grau-Sepulveda M, et al.
12 Mortality after esophagectomy: analysis of individual complications and their
13 association with mortality. *J Gastrointest Surg*. 2019 DOI: 10.1007/s11605-019-04346-
14 2
- 15 5 Ferguson MK, Durkin AE. Preoperative prediction of the risk of pulmonary
16 complications after esophagectomy for cancer. *J Thorac Cardiovasc Surg*.
17 2002;123(4):661–9.
- 18 6 Tabira Y, Okuma T, Kondo K, Yoshioka M, Mori T, Tanaka M, et al. Does neoadjuvant
19 chemotherapy for carcinoma in the thoracic esophagus increase postoperative

- 1 morbidity? *Jpn J Thorac Cardiovasc Surg.* 1999;47(8):361–7.
- 2 7 Raymond DP, Seder CW, Wright CD, Magee MJ, Kosinski AS, Cassivi SD, et al.
3 Predictors of major morbidity or mortality after resection for esophageal cancer : a
4 society of thoracic surgeons general thoracic surgery database risk adjustment model.
5 *Ann Thorac Surg.* 2016;102(1):207–14.
- 6 8 Mokart D, Giaoui E, Barbier L, Lambert J, Sannini A, Chow-Chine L, et al.
7 Postoperative sepsis in cancer patients undergoing major elective digestive surgery is
8 associated with increased long-term mortality. *J Crit Care.* 2016;31(1):48–53.
- 9 9 Abe H, Mafune K ichi. Risk factors for maintenance hemodialysis patients undergoing
10 elective and emergency abdominal surgery. *Surg Today.* 2014;44(10):1906–11.
- 11 10 Newman LA, Mittman N, Hunt Z, Alfonso AE. Survival among chronic renal failure
12 patients requiring major abdominal surgery. *J Am Coll Surg.* 1999;188(3):310–4.
- 13 11 Nakazato T, Nakamura T, Sekiya N, Sawa Y. Preoperative estimated glomerular
14 filtration rate is an independent predictor of late cardiovascular morbidity after mitral
15 valve surgery. *Ann Thorac Cardiovasc Surg.* 2014;20(5):390–7.
- 16 12 Wang F, Dupuis JY, Nathan H, Williams K. An analysis of the association between
17 preoperative renal dysfunction and outcome in cardiac surgery: estimated creatinine
18 clearance or plasma creatinine level as measures of renal function. *Chest.*
19 2003;124(5):1852–62.

- 1 13 Nagai M, Sho M, Akahori T, Tanaka T, Kinoshita S, Nishiofuku H, et al. Impact of
2 preoperative asymptomatic renal dysfunction on clinical course after
3 pancreatoduodenectomy. *J Hepatobiliary Pancreat Sci.* 2015;22(11):810–8.
- 4 14 Matsumoto S, Takayama T, Wakatsuki K, Tanaka T, Migita K, Nakajima Y. Short-term
5 and long-term outcomes after gastrectomy for gastric cancer in patients with chronic
6 kidney disease. *World J Surg.* 2014;38(6):1453–60.
- 7 15 Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for
8 estimated GFR from serum creatinine in Japan. *Am J Kidney Dis.* 2009;53(6): 982-92.
- 9 16 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new
10 proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg.*
11 2004;240(2):205–13.
- 12 17 Iii MHS, Lad NL, Fisher SB, Kooby DA, Weber SM, Brinkman A, et al. The effect of
13 preoperative renal insufficiency on postoperative outcomes after major hepatectomy : a
14 multi-institutional analysis of 1,170 patients. *J Am Coll Surg.* 2014;219(5):914–22.
- 15 18 Buise MP. Proper volume management during anesthesia for esophageal resection. *J*
16 *Thorac Dis.* 2019;11(10):S702–6.
- 17 19 McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and
18 hypertensive end-organ damage. *Circ Res.* 2015;116(6):1022–33.
- 19 20 White WE. Aging and uremia: Is there cellular and molecular crossover? *World J*

- 1 Nephrol. 2015;4(1):19-30.
- 2 21 Viana JL, Kosmadakis GC, Watson EL, Bevington A, Feehally J, Bishop NC, et al.
3 Evidence for anti-inflammatory effects of exercise in CKD. *J Am Soc Nephrol.*
4 2014;25(9):2121–30.
- 5 22 Uchihara T, Yoshida N, Baba Y, Yagi T, Toihata T, Oda E. Risk factors for pulmonary
6 morbidities after minimally invasive esophagectomy for esophageal cancer. *Surg*
7 *Endosc.* 2018;32(6):2852–8.
- 8 23 Ohi M, Toiyama Y, Omura Y, Ichikawa T, Yasuda H, Okugawa Y. Risk factors and
9 measures of pulmonary complications after thoracoscopic esophagectomy for
10 esophageal cancer. *Surg Today.* 2019;49(2):176–86.
- 11 24 Takeuchi H, Miyata H, Baba H, Shimada M, Mori M. A risk model for esophagectomy
12 using data of 5354 patients included in a japanese nationwide web-based database. *Ann*
13 *Surg,* 2014;260(2):259–66.
- 14 25 Zingg U, Smithers BM, Gotley DC, Smith G, Aly A, Clough A, et al. Factors associated
15 with postoperative pulmonary morbidity after esophagectomy for cancer. *Ann Surg*
16 *Oncol.* 2011;18(5):1460–8.
- 17
18
19

1 **Figure legends**

2 **Fig. 1** Distribution of the estimated glomerular filtration rate (eGFR) value. Patients with an
3 eGFR <55 ml/min per 1.73 m² were classified as the low eGFR group (white bar), while those
4 with an eGFR of ≥ 55 ml/min per 1.73 m² were classified as the normal eGFR group (black
5 bar).

6

7 **Fig. 2** The comparison of the overall survival between the low and normal eGFR groups.




Fig. 1




Fig. 2

Table 1 Patient characteristics

Variables	Normal eGFR (n = 160)	Low eGFR (n = 17)	P value
Age (years)	65 ± 7.0	73 ± 7.5	<0.01
Gender (%)			0.04
Male	130 (81%)	17 (100%)	
Female	30 (19%)	0 (0%)	
Co-morbidities (%)			
All	80 (50%)	12 (71%)	0.13
Diabetes mellitus	20 (13%)	2 (12%)	0.65
Hypertension	54 (34%)	10 (59%)	0.06
Respiratory disorder	8 (5%)	2 (12%)	0.25
Cardiovascular disease	10(6%)	3(18%)	0.12
Hemoglobin (g/dl)	13.4 ± 1.7	13.5 ± 1.6	0.88
Albumin (g/dl)	4.2 ± 0.42	4.3 ± 0.32	0.34
Serum creatinine (mg/dl)	0.76 ± 0.13	1.7 ± 2.4	<0.01
Tumor location (%)			0.06
Ut	23 (14%)	3 (18%)	
Mt	79 (49%)	5 (29%)	
Lt	40 (25%)	3 (18%)	
Others	18 (11%)	4 (24%)	
Tumor size (mm)	45.1 ± 26.1	35.7 ± 17.8	0.24
Primary tumor (%) ^a			0.31
cT0/1	64 (40%)	4 (24%)	
cT2	19 (12%)	5 (29%)	
cT3	75 (47%)	8 (47%)	
cT4a/4b	1 (1%)	0 (0%)	
Regional lymph nodes (%) ^a			
cN0	63 (39%)	10 (59%)	0.12
cN1	91 (57%)	5 (29%)	
cN2	4 (3%)	2 (12%)	
cN3	1 (1%)	0 (0%)	
cStage (%) ^a			0.29
IA/IB	43 (27%)	4 (24%)	
IIA/IIB	52 (33%)	9 (53%)	
IIIA/IIIB/IIIC	61 (38%)	4 (24%)	
IV	3(2%)	0 (0%)	
Primary tumor (%) ^a			0.81
pT0/1	91 (57%)	8 (47%)	
pT2	16 (10%)	2 (12%)	

pT3	52 (33%)	7 (41%)	
pT4a/4b	0 (0%)	0 (0%)	
Regional lymph nodes (%) ^a			0.23
pN0	79 (49%)	6 (35%)	
pN1	36 (23%)	4 (24%)	
pN2	27 (17%)	6 (35%)	
pN3	17 (11%)	1 (6%)	
pStage (%) ^a			0.46
0	9 (6%)	0 (%)	
IA/IB	53 (33%)	4 (24%)	
IIA/IIB	39 (24%)	3 (18%)	
IIIA/IIIB/IIIC	52 (33%)	10 (59%)	
IV	6 (4%)	0 (0%)	
Reconstructed substitute (%) ^a			0.50
Stomach	135 (84%)	15 (88%)	
Others	25 (16%)	2 (12%)	
Extent of lymphadenectomy (%) ^a			0.11
<2FL	31 (19%)	6 (35%)	
3FL	129 (81%)	11 (65%)	
Median number of dissected nodes	56.2 ± 23.8	49.2 ± 18.1	0.34
Residual tumor (%) ^a			0.17
R0	154 (96%)	15 (88%)	
R1	6 (4%)	2 (12%)	
Preoperative therapies (%)			0.07
Absence	59 (37%)	10 (59%)	
Presence	101 (63%)	7 (41%)	

eGFR estimated glomerular filtration rate, *UICC* Union for International Cancer Control,

FL field lymphadenectomy, ^a UICC 7th

Table 2 Perioperative data

Variables	Normal eGFR (<i>n</i> = 160)	Low eGFR (<i>n</i> = 17)	<i>P</i> value
Operative data			
Operating time (min)	563.9 ± 115.2	540.8 ± 146.0	0.34
Intraoperative blood loss (ml)	441.3 ± 524.7	284.1 ± 233.6	0.13
Postoperative complication			
All (%)	95 (59%)	13 (76%)	0.20
Anastomotic leakage	32 (20%)	4 (24%)	0.47
Recurrent laryngeal nerve palsy	15 (9%)	2 (12%)	0.51
Conduit trouble	7 (4%)	1 (6%)	0.56
Infection	14 (9%)	0 (0%)	0.23
Respiratory events	18 (11%)	6 (35%)	0.02
Cardiovascular events	3 (2%)	0 (0%)	0.74
Renal failure	1 (1%)	0 (0%)	0.90
Other	24 (15%)	4 (24%)	0.27
Clavien-Dindo classification (%)			0.04
Grade 0/I/II/IIIa	149 (93%)	13 (76%)	
Grade IIIb/IVa	11 (7%)	4 (24%)	

eGFR estimated glomerular filtration rate

Table 3 Risk factors of Clacian-Dindo classification IIIb and higher

	Univariable analysis			Multivariable analysis		
	OR	95% CI	<i>P</i> value	OR	95% CI	<i>P</i> value
Age (>65/≤65 years)	0.89	0.3-2.6	0.83	0.69	0.2-2.1	0.51
Gender (female/male)	1.25	0.3-4.7	0.74	-	-	-
Comorbidity (presence/absence)	1.95	0.6-6.0	0.24	-	-	-
Tumor location (others/Mt)	2.68	0.8-8.8	0.10	-	-	-
Tumor size (>40/≤40 mm)	0.62	0.2-1.8	0.38	-	-	-
Primary tumor (cT3-4/0-2) ^a	0.95	0.3-2.8	0.93	-	-	-
Regional lymph node (cN1-3/0) ^a	1.07	0.4-3.1	0.90	-	-	-
Extended lymphadenectomy (3/<2FL)	0.70	0.2-2.4	0.57	-	-	-
Preoperative therapies (presence/absence)	1.31	0.4-4.0	0.64	-	-	-
Hemoglobin (≤13.2/>13.2 g/dL)	2.84	1.0-8.4	0.06	-	-	-
Albumin (≤4.3/>4.3 g/dL)	1.92	0.7-5.7	0.23	-	-	-
Preoperative eGFR (<55/≥55 ml/min/1.73m ²)	4.17	1.1-14.9	0.03	4.70	1.2-17.9	0.02

eGFR estimated glomerular filtration rate, *OR* odds ratio, *CI* confidence interval, FL field lymphadenectomy

^aUICC 7th